Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 27, 2016

GSK initiates Phase III programme of daprodustat

UK drug manufacturer GlaxoSmithKline (GSK) has initiated its Phase III programme of daprodustat being developed to treat anaemia associated with chronic kidney disease (CKD).

UK drug manufacturer GlaxoSmithKline (GSK) has initiated its Phase III programme of daprodustat being developed to treat anaemia associated with chronic kidney disease (CKD).

Daprodustat has been developed as an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, which induces production of red blood cells that carry oxygen to where it is needed.

The Phase III programme is characterised by two studies, ASCEND-D, which will enrol approximately 3,000 dialysis dependent patients with anaemia associated with CKD, changing from an erythropoietin-stimulating agent (ESA).

ASCEND-ND is the other study planning to enrol approximately 4,500 non-dialysis dependent subjects with CKD-related anaemia who are either changing to ESA or are naïve to the regimen.

Both studies will be conducted to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin.

"For many patients with chronic kidney disease, treating their anaemia comes with risks associated with cardiovascular safety and injectable administration."

The studies will be primarily focused on determining the time taken for the first occurrence of major adverse cardiovascular events (MACE) and baseline change in haemoglobin.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

GSK innovation performance and technology vice-president Julian Jenkins said: “For many patients with chronic kidney disease, treating their anaemia comes with risks associated with cardiovascular safety and injectable administration.

“The start of phase III studies of daprodustat is an important step in our work to explore whether daprodustat could address those risks and provide a potential alternative, oral treatment option.”

The phase III programme is based on the data of phase II clinical trials, which were intended to characterise the dose-response relationship between daprodustat and haemoglobin at four weeks and test the safety and tolerability of daprodustat following once-daily administration up to 24 weeks.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU